Ecopipam Linked to Lower Tic Relapse Risk in Pediatric Individuals With Tourette Syndrome
KEY TAKEAWAYS
- Treatment with ecopipam was associated with a 50% lower risk of tic relapse vs placebo in pediatric patients with Tourette syndrome in a phase 3 randomized withdrawal trial.
- A review article highlighted sustained tic improvement after ecopipam treatment without clinically relevant weight gain or metabolic complications.
- Ecopipam was previously granted FDA Priority Review for pediatric Tourette syndrome.
Treatment with ecopipam (Teva Pharmaceuticals, Parsippany, NJ) was associated with a 50% lower risk of tic relapse than placebo in pediatric patients with Tourette syndrome according to results of a phase 3 randomized withdrawal trial, D1AMOND (NCT05615220). A review article published in the Journal of Child Neurology places those findings in the context of phase 2b, phase 3, and long-term open-label data and examines selective dopamine D1 receptor antagonism as a potential nonantipsychotic approach to tic management.
Ecopipam is an investigational selective dopamine D1 receptor antagonist that targets dopaminergic signaling in the direct motor pathway. In contrast with antipsychotic therapies that primarily act through D2 receptors in the indirect pathway, selective D1 receptor antagonism has been proposed as a way to reduce tic severity while potentially avoiding some adverse effects associated with D2-targeting agents.
What the Clinical Data Showed
- Tic relapse: In the phase 3 D1AMOND trial (n=216, including 167 pediatric participants), ecopipam treatment was associated with a 50% lower relapse risk versus placebo among pediatric participants (hazard ratio, 0.50; P=.008).
- Sustained improvement: Phase 2b and 12-month extension data demonstrated sustained reductions in tic severity.
- Safety: Common adverse events included somnolence, headache, insomnia, fatigue, and anxiety. No clinically relevant weight gain, metabolic complications, or drug-induced movement disorders were reported across trials.
Clinical Implications for Neurologists
The findings highlight D1 receptor antagonism as a potential alternative to D2-targeting therapies for pediatric Tourette syndrome, particularly when balancing tic control with treatment-related adverse effects. However, the phase 3 randomized withdrawal trial assessed maintenance of response among stabilized participants, and direct comparative evidence against D2 antagonists remains limited.
Ecopipam is not approved by the Food and Drug Administration (FDA) for Tourette syndrome, although its pediatric application has received Priority Review and Orphan Drug designation.
Source
- Karkanias GB, Flatt JA, Korb RT, et al. Targeting dopamine pathways for the treatment of Tourette syndrome. J Child Neurol. Published online 2026. doi:10.1177/08830738261491159
- Gilbert DL, Atkinson SD, Kim DJB, et al. Efficacy and safety of ecopipam for Tourette syndrome: a phase 3 randomized clinical trial. JAMA Neurol. 2026;83(7):645-653. doi:10.1001/jamaneurol.2026.1431
- Teva Pharmaceuticals. Journal of Child Neurology Publishes Review Highlighting Dopamine's Role in Tourette Syndrome and Ecopipam's Selective D1 Receptor Mechanism for Tourette Syndrome in Pediatric Patients. Published October 2, 2026. Accessed October 9, 2026. https://www.tevapharm.com/news-and-media/latest-news/journal-of-child-neurology-publishes-review-highlighting-dopamines-role-in-tourette-syndrome-and-ecopipa/